Radotinib-induced eruptive melanocytic nevi in patient with chronic myeloid leukemia: a case report and literature review

Park, Eun-Jung; Jue, Mihn‐Sook

doi:10.1007/s00277-018-3444-0

Search citation statements

Order By: Relevance

Paper Sections

Select...

Development Of Novel Tyrosine Kinase Inhibitors1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Third generation TKIs also include radotinib, a TKI with structural similarities to imatinib and nilotinib, which was approved in Korea in 2012 for the second-line treatment of CML [73]. This TKI is one of the most effective treatments for chronic phase CML [74] but has side effects including pigment changes such as eruptive melanocytic nevi [75].…”

Section: Development Of Novel Tyrosine Kinase Inhibitorsmentioning

confidence: 99%

HDAC6—An Emerging Target Against Chronic Myeloid Leukemia?

Losson

Schnekenburger

Dicato

et al. 2020

Cancers

View full text Add to dashboard Cite

Imatinib became the standard treatment for chronic myeloid leukemia (CML) about 20 years ago, which was a major breakthrough in stabilizing the pathology and improving the quality of life of patients. However, the emergence of resistance to imatinib and other tyrosine kinase inhibitors leads researchers to characterize new therapeutic targets. Several studies have highlighted the role of histone deacetylase 6 (HDAC6) in various pathologies, including cancer. This protein effectively intervenes in cellular activities by its primarily cytoplasmic localization. In this review, we will discuss the molecular characteristics of the HDAC6 protein, as well as its overexpression in CML leukemic stem cells, which make it a promising therapeutic target for the treatment of CML.

show abstract

Section: Development Of Novel Tyrosine Kinase Inhibitorsmentioning

confidence: 99%